Research Article
The Efficacy and Cost-Effectiveness of Umeclidinium/Vilanterol versus Tiotropium in Symptomatic Patients with Chronic Obstructive Pulmonary Disease
Table 4
Treatment-related costs of chronic obstructive pulmonary disease.
| | Input parameter | Value | Source/assumption |
| | Drug costs | Quarterly prescription costs (calculated based on the winning bid price in 2020) | | | UMEC/VI | $95.22 | http://www.yaozh.com | | TIO | $180.53 | http://www.yaozh.com |
| | Other medical costs | Quarterly costs | | | Moderate COPD | $143.37 | Reference [14] | | Severe COPD | $204.29 | | | Very severe COPD | $319.45 | Physician visit: local charge |
| | Adverse events (AEs) | Costs a (per reported AE) | Physician visit and local processing charge | | Back pain | $3.19 | Physician visit: local charge | | Cough | $32.2 | Physician visit: local charge | | Headache | $3.19 | Physician visit and local processing charge | | Nasopharyngitis | $3.19 | | | Upper respiratory tract infection | $39.21 | |
| | Exacerbation cost | | | | Severe exacerbation | $2,129.690 | | | Nonsevere exacerbation | $44.824 | |
|
|
